Pancreatic cancer is one of the deadliest malignancies, with survival rates remaining dismally low despite major advances in oncology. One of the key reasons lies in the disease’s unique fibrotic microenvironment—a dense, collagen-rich tissue that acts as a physical and biochemical barrier, preventing drugs from reaching tumor cells effectively.
Blocking collagen signaling boosts drug delivery in pancreatic cancer
